irbesartan + ramipril

This is a combination of **irbesartan**, an angiotensin II receptor blocker (ARB), and **ramipril**, an angiotensin-converting enzyme (ACE) inhibitor. Both drugs are antihypertensives that act on the renin-angiotensin system via complementary mechanisms—ramipril inhibits the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone secretion, while irbesartan directly blocks angiotensin II at the AT1 receptor. This combination is intended to achieve greater reduction in blood pressure or proteinuria when monotherapy is inadequate. However, clinical evidence indicates that combining an ARB and an ACE inhibitor only marginally improves blood pressure control, and dual blockade therapy is associated with increased risk of adverse effects such as hyperkalemia and acute renal failure[2][3]. There are no unique fixed-dose formulations or brand names commonly marketed for this specific combination; its use (if any) is typically off-label or in clinical trials.

Brand names

AvaproKarveaKarvezideIfirmacombi